Wolfson Centre for Prevention of Stroke and Dementia
We increase understanding of the causes of cerebrovascular disease and improve the prevention of stroke and vascular dementia in routine clinical practice.
t: 01865 231601
The Wolfson Centre for the Prevention of Stroke and Dementia (CPSD) is the UK’s first purpose-built research centre focussed specifically on prevention of cerebrovascular disease. The CPSD builds on the Stroke Prevention Research Unit (SPRU), which was founded by Professor Rothwell in 2000 and was awarded a Queen’s Anniversary Prize for Higher Education in 2014 in recognition of the impact of our research on healthcare.
The CPSD building was funded by peer-reviewed capital grants from the Wolfson Foundation and the Wellcome Trust and was officially opened in March 2020. The Centre provides 2000 M2 of research space, including a clinical research facility, laboratory support and housing for our cohort studies, clinical trials and biobanks. The CPSD currently has 40-50 research and support staff and is one of the most productive cerebrovascular research groups in the world.
A key feature of the Centre is the focus on both of the main clinical manifestations of cerebrovascular disease. Stroke and dementia are the most common neurological causes of premature death and disability in adults and frequently co-exist, each increasing the risk of the other. Cerebrovascular disease contributes to the majority of cases of dementia at older ages and dementia increases the risk and severity of stroke. Stroke and dementia also require similar research resources (e.g. brain imaging, elderly controls) and so parallel protocols can reduce costs. Moreover, since end-organ damage due to vascular disease is amenable to prevention, the vascular contribution to neurodegeneration needs to be better understood. Our mechanistic research programme therefore focuses on vascular risk factors, arterial stiffness, white matter disease, and cerebral perfusion, and our clinical research programme aims to improve prevention and outcome by better understanding of known vascular risk factors and more effective use of existing treatments.
As vascular disease is rarely limited to one organ, the Centre also has research programmes focusing on coronary artery disease and peripheral arterial disease and on topics common to vascular disease at all sites, including hypertension and the risks and benefits of aspirin and other antithrombotic drugs.
17 January 2020
Researchers in our Centre for the Prevention of Stroke and Dementia have begun a clinical trial to assess whether the drug sildenafil could improve blood flow to the brain.
13 September 2019
The charity has provided £126K of funding for one 3-year clinical research fellowship starting in January 2020.
2 May 2019
Risk of dementia after stroke is a major concern for patients and carers. Reliable data on risk of dementia, particularly after TIA or minor stroke, are scarce.
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies
Li L. et al, (2021), The Lancet Neurology, 20, 437 - 447
Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis
Tuna MA. and Rothwell PM., (2021), The Lancet, 397, 902 - 912
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.
Howard DPJ. et al, (2021), Lancet Neurol, 20, 193 - 202
Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review.
Mazzucco S. et al, (2020), JAMA neurology
Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study.
Hurford R. et al, (2020), Lancet Neurol, 19, 413 - 421